Cenderitide

Cardiovascular

Also known as: CD-NP

Natriuretic Peptides (Engineered)Research phase: Phase 2Regulatory: Not approved. Investigational for heart failure.

Mechanism

Cenderitide is an engineered chimeric peptide combining CNP and Dendroaspis natriuretic peptide (DNP) that activates both natriuretic peptide receptors. It was designed to protect the heart and kidneys in heart failure.

Technical detail

Cenderitide (CD-NP) is a 37-amino acid chimeric peptide fusing the 22-residue ring of C-type natriuretic peptide (CNP) with the 15-residue C-terminus of Dendroaspis natriuretic peptide (DNP). It co-activates both NPR-A (cGMP/natriuresis) and NPR-B (anti-fibrotic/anti-hypertrophic), providing combined cardiorenal protection. Phase 2 trials in heart failure showed favorable renal and neurohumoral effects.

Evidence

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
Kawakami R et al. (2018) — Clinical Pharmacology and Therapeutics — PMID: 29226471
First-in-human study in stable chronic heart failure found cenderitide was tolerated and activated cyclic GMP signaling, supporting biologic activity without overclaiming clinical efficacy from an early-phase design.
moderate

Build a personalized protocol with Cenderitide →